Accelerating Global Cooperation: Tee Labs and MTPC Corporate Partnering Meeting Facilitates Global Expansion for Innovative Pharma Companies
Accelerating International Cooperation: Tee Labs and Mitsubishi Tanabe Partner to Support the Global Expansion of Chinese Biotech
China’s pharmaceutical industry is advancing towards a deeper level of internationalization. Early-stage domestic biopharmaceutical companies are also actively accelerating the internationalization of their technologies, entering the global market, and exploring paths for global expansion. Recently, Tee Labs and Mitsubishi Tanabe Pharma Corporation (MTPC), a wholly-owned subsidiary of Mitsubishi Chemical Group, held a corporate partnering meeting, establishing a key platform to promote cooperation and exchange and to advance development in the field of pharmaceutical R&D. Mitsubishi Tanabe is the sixth-largest pharmaceutical company in Japan, with a history of over 300 years and sales figures that rank it among the top 50 pharmaceutical companies worldwide. The company possesses strong R&D capabilities, a wealth of technological expertise, and a global strategic layout, committed to driving continuous development and innovation in the pharmaceutical sector. This partnering meeting serves as a microcosm of the current trend where Chinese biotech companies are actively seeking opportunities for global expansion.
While China’s homegrown innovative drugs are on the rise, domestically developed drugs face challenges including high R&D costs, intense competition, and pressure from national healthcare insurance negotiations, which in turn puts pressure on the returns for new drugs. Consequently, companies are increasingly seeking development paths in the international market. For biopharmaceutical companies in the early stages of development, plans for international cooperation in R&D are more common, including various options such as scientific collaboration and licensing agreements.
However, companies in their early stages still face several pain points during their global expansion process. Firstly, there are misconceptions about the optimal timing for going global. Many companies tend to consider licensing and commercial partnerships only after filing an IND (Investigational New Drug) application or obtaining Phase II clinical results, thereby missing earlier partnership opportunities. When a company pursues global expansion at a late stage, it faces numerous challenges, such as higher costs for out-licensing, very high clinical trial costs, and the need to manage sales pressure. This leads to a smaller pool of potential buyers, making the company’s negotiations more difficult and increasing time costs. Therefore, early-stage biopharmaceutical companies can more proactively consider international cooperation, planning for licensing and commercial partnerships from the early phases of product development to increase the likelihood of successful collaboration.
Additionally, “choosing the right partner” is also key to successful global expansion. It is essential to select partners who are suited to the rules of the local market. At the right time, finding the right professionals to communicate with overseas companies is crucial, which includes screening potential international partners and communicating with their internal decision-makers. Leveraging professional talent or consulting firms, combined with the successful experience and resources of partners, can help address local integration challenges and achieve better international cooperation and development.
As an incubator focused on innovation in biopharmaceuticals, Tee Labs successfully hosted the “Corporate Partnering Meeting” with Mitsubishi Tanabe, building an important platform to address the pain points of companies aiming for global expansion.
Prior to this meeting, Mitsubishi Tanabe provided Tee Labs with a list of its requirements. Based on this list, Tee Labs assisted in screening suitable startups and arranged meetings with several companies. Mitsubishi Tanabe dispatched a high-level delegation, consisting of its offline R&D strategy department, the head of the Asia-Pacific region, and online global scientists, to participate in the meeting. This was to ensure that key decisions could be made and strategic support could be provided during the discussions, and it also added more professional perspectives to the meeting. During the event, to protect the commercial intelligence and technical information of the partnering companies, each company had a one-on-one meeting with Mitsubishi Tanabe, ensuring information security and confidentiality. This personalized meeting format allowed both parties to explore collaboration possibilities more deeply, while also making the partnering companies feel more secure and confident. Many of the attendees were the CEOs or Chief Scientific Officers of their companies; they possessed a deep and comprehensive understanding of their company’s science and products, showcased their leading technical capabilities and innovative R&D achievements, and enhanced their company’s visibility.
Through the partnering meeting, startups had the opportunity to engage in in-depth exchanges with an international pharmaceutical company, understand the needs and trends of the global pharmaceutical market, and gain valuable insights and potential partnership opportunities for their future overseas development. A relevant representative from Mitsubishi Tanabe stated that through this meeting, they were impressed by the level of innovation at Chinese biopharmaceutical companies and look forward to further discussions and collaboration with them. Through this event, Tee Labs hopes to foster a “win-win” ecosystem, promote cooperation and exchange between startups and international innovative pharmaceutical companies, and jointly address the challenges of the current “winter” in the innovative pharmaceutical sector. This partnering meeting was an international matchmaking opportunity provided by Tee Labs to companies free of charge, reflecting Tee Labs’ commitment to promoting the development of the innovative pharmaceutical industry. It received high recognition and positive feedback from companies within its network and the Mitsubishi Tanabe team, and is poised to bring new opportunities for cooperation and development to the innovative pharmaceutical sector.
About Tee Labs
Tee Labs is an international community and business incubator founded through a collaboration of entrepreneurs and venture capitalists, dedicated to supporting the development of pioneering medical fields, including new drug discovery, diagnostics, and personalized medicine that incorporate artificial intelligence and digital solutions.
We provide comprehensive support, including R&D facilities, corporate functions, supply chain integration, and financial backing, to deeply empower entrepreneurial teams and accelerate their R&D progress. The laboratories are equipped with basic, general-purpose experimental equipment as well as shared equipment platforms, significantly shortening the setup phase for startups in terms of facilities and equipment, allowing companies to focus on their core R&D work.
The incubator is located in the central area of Zhangjiang Science City, in a park at the Zhongke Road station exit of Metro Line 13, near the Jinke Road exit of the Middle Ring Road. The park is adjacent to research institutions such as ShanghaiTech University, the Shanghai Institute for Advanced Immunochemical Studies, and the National Center for Protein Science, placing it in the core development zone of Zhangjiang Science City. It is a core hub integrating research, living, and transportation.
Currently, Tee Labs has approximately 2,600 square meters of incubation space, of which 1,500 square meters are dedicated to laboratory areas, including chemistry, molecular biology, cell culture, bacterial culture, and BSL-2 labs. The variety of laboratory spaces can support companies with different R&D directions, allowing early-stage companies to have multi-functional teams working together in the same space.